O	0	10	Randomized
O	11	17	Double
O	17	18	-
O	18	23	Blind
O	24	31	Placebo
O	31	32	-
O	32	42	Controlled
O	43	52	Biomarker
O	53	63	Modulation
O	64	69	Study
O	70	72	of
B-intervention	73	80	Vitamin
I-intervention	81	82	D
I-intervention	83	98	Supplementation
O	99	101	in
O	102	115	Premenopausal
O	116	121	Women
O	122	124	at
O	125	129	High
O	130	134	Risk
O	135	138	for
O	139	145	Breast
O	146	152	Cancer
O	153	154	(
O	154	158	SWOG
O	159	164	S0812
O	164	165	)
O	165	166	.

O	167	180	Observational
O	181	188	studies
O	189	193	have
O	194	202	reported
O	203	205	an
O	206	213	inverse
O	214	225	association
O	226	233	between
O	234	241	vitamin
O	242	243	D
O	244	250	intake
O	251	254	and
O	255	261	breast
O	262	268	cancer
O	269	273	risk
O	273	274	.

O	275	277	We
O	278	286	examined
O	287	294	whether
O	295	302	vitamin
O	303	304	D
O	305	320	supplementation
O	321	323	in
O	324	328	high
O	328	329	-
O	329	333	risk
O	334	347	premenopausal
O	348	353	women
O	354	361	reduces
O	362	374	mammographic
O	375	382	density
O	383	384	(
O	384	386	MD
O	386	387	)
O	387	388	,
O	389	391	an
O	392	403	established
O	404	410	breast
O	411	417	cancer
O	418	422	risk
O	423	429	factor
O	429	430	.

O	431	433	We
O	434	443	conducted
O	444	445	a
O	446	457	multicenter
O	458	468	randomized
O	469	475	double
O	475	476	-
O	476	481	blind
O	482	489	placebo
O	489	490	-
O	490	500	controlled
O	501	506	trial
O	507	509	in
B-eligibility	510	523	premenopausal
I-eligibility	524	529	women
I-eligibility	530	532	at
I-eligibility	533	537	high
I-eligibility	538	542	risk
I-eligibility	543	546	for
I-eligibility	547	553	breast
I-eligibility	554	560	cancer
O	561	562	[
O	562	563	5
O	563	564	-
O	564	568	year
O	569	573	risk
O	574	575	≥
O	576	577	1
O	577	578	.
O	578	580	67
O	580	581	%
O	581	582	,
O	583	591	lifetime
O	592	596	risk
O	597	598	≥
O	599	601	20
O	601	602	%
O	602	603	,
O	604	611	lobular
O	612	621	carcinoma
O	622	624	in
O	625	629	situ
O	629	630	,
O	631	636	prior
O	637	642	stage
O	643	644	0
O	644	645	-
O	645	647	II
O	648	654	breast
O	655	661	cancer
O	661	662	,
O	663	673	hereditary
O	674	680	breast
O	681	687	cancer
O	688	696	syndrome
O	696	697	,
O	698	700	or
O	701	705	high
O	706	708	MD
O	709	710	(
O	710	725	heterogeneously
O	725	726	/
O	726	735	extremely
O	736	741	dense
O	741	742	)
O	742	743	]
O	743	744	,
O	745	749	with
O	750	751	a
O	752	760	baseline
O	761	766	serum
O	767	769	25
O	769	770	-
O	770	784	hydroxyvitamin
O	785	786	D
O	787	788	[
O	788	790	25
O	790	791	(
O	791	793	OH
O	793	794	)
O	794	795	D
O	795	796	]
O	797	798	≤
O	799	801	32
O	802	804	ng
O	804	805	/
O	805	807	mL
O	807	808	.

O	809	821	Participants
O	822	826	were
O	827	837	randomized
O	838	840	to
O	841	843	12
O	844	850	months
O	851	853	of
O	854	861	vitamin
O	862	864	D3
O	865	867	20
O	867	868	,
O	868	871	000
O	872	874	IU
O	874	875	/
O	875	879	week
O	880	882	or
O	883	891	matching
B-control	892	899	placebo
O	899	900	.

O	901	904	The
O	905	912	primary
O	913	921	endpoint
O	922	925	was
B-outcome-Measure	926	932	change
I-outcome-Measure	933	935	in
I-outcome-Measure	936	938	MD
I-outcome-Measure	939	943	from
I-outcome-Measure	944	952	baseline
I-outcome-Measure	953	955	to
I-outcome-Measure	956	958	12
I-outcome-Measure	959	965	months
O	966	971	using
O	972	975	the
O	976	983	Cumulus
O	984	993	technique
O	993	994	.

O	995	1004	Secondary
O	1005	1014	endpoints
O	1015	1023	included
B-outcome-Measure	1024	1030	serial
I-outcome-Measure	1031	1036	blood
I-outcome-Measure	1037	1047	biomarkers
O	1048	1049	[
O	1049	1051	25
O	1051	1052	(
O	1052	1054	OH
O	1054	1055	)
O	1055	1056	D
O	1056	1057	,
O	1058	1059	1
O	1059	1060	,
O	1060	1062	25
O	1062	1063	-
O	1063	1079	dihydroxyvitamin
O	1080	1081	D
O	1082	1083	(
O	1083	1084	1
O	1084	1085	,
O	1085	1087	25
O	1087	1088	(
O	1088	1090	OH
O	1090	1091	)
O	1091	1092	D
O	1092	1093	)
O	1093	1094	,
O	1095	1102	insulin
O	1102	1103	-
O	1103	1107	like
O	1108	1114	growth
O	1115	1121	factor
O	1122	1123	(
O	1123	1126	IGF
O	1126	1127	)
O	1127	1128	-
O	1128	1129	1
O	1129	1130	,
O	1131	1134	IGF
O	1134	1135	-
O	1135	1142	binding
O	1143	1150	protein
O	1150	1151	-
O	1151	1152	3
O	1152	1153	]
O	1154	1157	and
B-outcome-Measure	1158	1160	MD
O	1161	1167	change
O	1168	1170	at
O	1171	1173	24
O	1174	1180	months
O	1180	1181	.

O	1182	1187	Among
B-total-participants	1188	1191	208
O	1192	1197	women
O	1198	1208	randomized
O	1208	1209	,
O	1210	1216	median
O	1217	1220	age
O	1221	1224	was
B-age	1225	1227	44
I-age	1227	1228	.
I-age	1228	1229	6
I-age	1230	1235	years
O	1235	1236	,
O	1237	1239	84
O	1239	1240	%
O	1241	1245	were
B-ethinicity	1246	1251	white
O	1251	1252	,
O	1253	1255	33
O	1255	1256	%
O	1257	1260	had
O	1261	1269	baseline
O	1270	1272	25
O	1272	1273	(
O	1273	1275	OH
O	1275	1276	)
O	1276	1277	D
O	1278	1279	<
O	1280	1282	20
O	1283	1285	ng
O	1285	1286	/
O	1286	1288	mL
O	1288	1289	,
O	1290	1293	and
O	1294	1296	78
O	1296	1297	%
O	1298	1301	had
O	1302	1306	high
O	1307	1315	baseline
O	1316	1318	MD
O	1318	1319	.

O	1320	1329	Comparing
O	1330	1333	the
O	1334	1340	active
O	1341	1344	and
O	1345	1352	placebo
O	1353	1359	groups
O	1360	1362	at
O	1363	1365	12
O	1366	1372	months
O	1372	1373	,
O	1374	1376	MD
O	1377	1384	changes
O	1385	1389	were
O	1390	1395	small
O	1396	1399	and
O	1400	1403	did
O	1404	1407	not
O	1408	1421	significantly
O	1422	1428	differ
O	1428	1429	.

B-outcome	1430	1434	Mean
I-outcome	1435	1437	MD
I-outcome	1438	1445	changes
I-outcome	1446	1448	at
I-outcome	1449	1451	12
I-outcome	1452	1455	and
I-outcome	1456	1458	24
I-outcome	1459	1465	months
O	1466	1470	were
B-iv-cont-mean	1471	1472	-
I-iv-cont-mean	1472	1473	0
I-iv-cont-mean	1473	1474	.
I-iv-cont-mean	1474	1475	3
I-iv-cont-mean	1475	1476	%
O	1477	1480	and
B-cv-cont-mean	1481	1482	-
I-cv-cont-mean	1482	1483	1
I-cv-cont-mean	1483	1484	.
I-cv-cont-mean	1484	1485	2
I-cv-cont-mean	1485	1486	%
O	1486	1487	,
O	1488	1500	respectively
O	1500	1501	,
O	1502	1504	in
O	1505	1508	the
O	1509	1515	active
O	1516	1519	arm
O	1520	1523	and
B-iv-cont-mean	1524	1525	+
I-iv-cont-mean	1525	1526	1
I-iv-cont-mean	1526	1527	.
I-iv-cont-mean	1527	1528	5
I-iv-cont-mean	1528	1529	%
O	1530	1533	and
B-cv-cont-mean	1534	1535	+
I-cv-cont-mean	1535	1536	1
I-cv-cont-mean	1536	1537	.
I-cv-cont-mean	1537	1538	6
I-cv-cont-mean	1538	1539	%
O	1540	1544	with
O	1545	1552	placebo
O	1553	1554	(
O	1554	1555	P
O	1556	1557	>
O	1558	1559	0
O	1559	1560	.
O	1560	1562	05
O	1562	1563	)
O	1563	1564	.

O	1565	1567	We
O	1568	1576	observed
O	1577	1578	a
B-outcome	1579	1583	mean
I-outcome	1584	1590	change
I-outcome	1591	1593	in
I-outcome	1594	1599	serum
I-outcome	1600	1602	25
I-outcome	1602	1603	(
I-outcome	1603	1605	OH
I-outcome	1605	1606	)
I-outcome	1606	1607	D
O	1608	1610	of
B-iv-cont-mean	1611	1612	+
I-iv-cont-mean	1612	1614	18
I-iv-cont-mean	1614	1615	.
I-iv-cont-mean	1615	1616	9
O	1617	1623	versus
B-cv-cont-mean	1624	1625	+
I-cv-cont-mean	1625	1626	2
I-cv-cont-mean	1626	1627	.
I-cv-cont-mean	1627	1628	8
I-cv-cont-mean	1629	1631	ng
I-cv-cont-mean	1631	1632	/
I-cv-cont-mean	1632	1634	mL
O	1635	1636	(
O	1636	1637	P
O	1638	1639	<
O	1640	1641	0
O	1641	1642	.
O	1642	1644	01
O	1644	1645	)
O	1646	1649	and
B-outcome	1650	1653	IGF
I-outcome	1653	1654	-
I-outcome	1654	1655	1
O	1656	1658	of
B-iv-cont-mean	1659	1660	-
I-iv-cont-mean	1660	1661	9
I-iv-cont-mean	1661	1662	.
I-iv-cont-mean	1662	1663	8
O	1664	1670	versus
B-cv-cont-mean	1671	1672	-
I-cv-cont-mean	1672	1673	1
I-cv-cont-mean	1673	1674	.
I-cv-cont-mean	1674	1675	8
I-cv-cont-mean	1676	1678	ng
I-cv-cont-mean	1678	1679	/
I-cv-cont-mean	1679	1681	mL
O	1682	1683	(
O	1683	1684	P
O	1685	1686	=
O	1687	1688	0
O	1688	1689	.
O	1689	1691	28
O	1691	1692	)
O	1692	1693	,
O	1694	1706	respectively
O	1706	1707	.

O	1708	1710	At
O	1711	1713	12
O	1714	1720	months
O	1720	1721	,
B-outcome	1722	1724	MD
O	1725	1728	was
O	1729	1739	positively
O	1740	1750	correlated
O	1751	1755	with
B-outcome	1756	1761	serum
I-outcome	1762	1765	IGF
I-outcome	1765	1766	-
I-outcome	1766	1767	1
O	1768	1771	and
B-outcome	1772	1775	IGF
I-outcome	1775	1776	-
I-outcome	1776	1777	1
I-outcome	1777	1778	/
I-outcome	1778	1783	IGFBP
I-outcome	1783	1784	-
I-outcome	1784	1785	3
O	1786	1787	(
O	1787	1788	P
O	1789	1790	<
O	1791	1792	0
O	1792	1793	.
O	1793	1795	01
O	1795	1796	)
O	1796	1797	.

O	1798	1802	This
O	1803	1808	trial
O	1809	1813	does
O	1814	1817	not
O	1818	1825	support
O	1826	1829	the
O	1830	1833	use
O	1834	1836	of
O	1837	1844	vitamin
O	1845	1846	D
O	1847	1862	supplementation
O	1863	1866	for
O	1867	1873	breast
O	1874	1880	cancer
O	1881	1885	risk
O	1886	1895	reduction
O	1895	1896	.
